Scientists identify genes that hinder CRISPR gene‑therapy delivery

Lipid‑nanoparticle (LNP) carriers are the backbone of many modern gene‑therapy treatments, yet their journey from bloodstream to the nucleus of a target cell is fraught with obstacles. Once administered, an LNP must first fuse with or be endocytosed by the plasma membrane of the intended cell. Failure to enter the cell efficiently limits the amount of therapeutic nucleic acid that can reach its destination.

After internalization, the LNP encounters a crowded intracellular environment. Organelles such as the endoplasmic reticulum, Golgi apparatus, and mitochondria can sequester or degrade the payload, diverting it from the nucleus and potentially causing off‑target effects. These intracellular detours reduce therapeutic efficacy and raise safety concerns, underscoring the need for improved targeting and release strategies.

Researchers are therefore focused on engineering LNPs with enhanced membrane‑fusion capabilities and organelle‑avoidance features, as well as developing precise delivery triggers that release the genetic material only upon reaching the nucleus. Advances in these areas promise to increase the reliability and safety of gene‑therapy platforms, bringing them closer to widespread clinical use.